<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Proc Natl Acad Sci U S A</journal-id>
<journal-id journal-id-type="iso-abbrev">Proc. Natl. Acad. Sci. U.S.A</journal-id>
<journal-id journal-id-type="hwp">pnas</journal-id>
<journal-id journal-id-type="pmc">pnas</journal-id>
<journal-id journal-id-type="publisher-id">PNAS</journal-id>
<journal-title-group>
<journal-title>Proceedings of the National Academy of Sciences of the United States of America</journal-title>
</journal-title-group>
<issn pub-type="ppub">0027-8424</issn>
<issn pub-type="epub">1091-6490</issn>
<publisher>
<publisher-name>National Academy of Sciences</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">26621748</article-id>
<article-id pub-id-type="pmc">4687542</article-id>
<article-id pub-id-type="publisher-id">201512957</article-id>
<article-id pub-id-type="doi">10.1073/pnas.1512957112</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Biological Sciences</subject>
<subj-group>
<subject>Neuroscience</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Ack1 is a dopamine transporter endocytic brake that rescues a trafficking-dysregulated ADHD coding variant</article-title>
<alt-title alt-title-type="short">Ack1 is a dopamine transporter endocytic brake</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Wu</surname>
<given-names>Sijia</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bellve</surname>
<given-names>Karl D.</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>b</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fogarty</surname>
<given-names>Kevin E.</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>b</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Melikian</surname>
<given-names>Haley E.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
<xref ref-type="corresp" rid="cor1">
<sup>1</sup>
</xref>
</contrib>
<aff id="aff1"><sup>a</sup>Brudnick Neuropsychiatric Research Institute, <institution>University of Massachusetts Medical School</institution>, Worcester, <addr-line>MA</addr-line> 01604;</aff>
<aff id="aff2"><sup>b</sup>Biomedical Imaging Group, Program in Molecular Medicine, <institution>University of Massachusetts Medical School</institution>, Worcester, <addr-line>MA</addr-line> 01605</aff>
</contrib-group>
<author-notes>
<corresp id="cor1"><sup>1</sup>To whom correspondence should be addressed. Email: <email>Haley.Melikian@umassmed.edu</email>.</corresp>
<fn fn-type="edited-by">
<p>Edited by Leslie Lars Iversen, University of Oxford, Oxford, United Kingdom, and approved November 4, 2015 (received for review July 3, 2015)</p>
</fn>
<fn fn-type="con">
<p>Author contributions: S.W., K.D.B., K.E.F., and H.E.M. designed research; S.W. performed research; K.D.B. and K.E.F. contributed new reagents/analytic tools; S.W. and H.E.M. analyzed data; S.W. and H.E.M. wrote the paper; and K.D.B. provided technical support for TIRF microscopy experiments.</p>
</fn>
<fn fn-type="conflict">
<p>The authors declare no conflict of interest.</p>
</fn>
</author-notes>
<pub-date pub-type="ppub">
<day>15</day>
<month>12</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="epub">
<day>30</day>
<month>11</month>
<year>2015</year>
</pub-date>
<volume>112</volume>
<issue>50</issue>
<fpage>15480</fpage>
<lpage>15485</lpage>
<self-uri xlink:href="pnas.201512957.pdf" xlink:title="pdf"></self-uri>
<abstract abstract-type="executive-summary">
<title>Significance</title>
<p>The dopamine (DA) transporter (DAT) stringently controls brain DA levels. Several addictive psychostimulants, antidepressants, and attention-deficit/hyperactivity disorder (ADHD) therapeutics inhibit DAT function, and multiple DAT mutants have been reported in ADHD, autism spectrum disorder, and infantile Parkinsonism. Given that aberrant DAT function underlies many pathological conditions, it is critical to understand intrinsic regulatory mechanisms that modulate DAT function. DAT availability at the cell surface is dynamically modulated, but the mechanisms controlling this process are not well understood. In the current study, we identified the penultimate mechanism that controls DAT stability at the cell surface. Moreover, by genetically manipulating this mechanism, we successfully rescued an ADHD-associated DAT mutant with intrinsic membrane instability. Thus, targeting DAT regulatory mechanisms may be a viable approach for treating dysregulated DAT.</p>
</abstract>
<abstract>
<p>The dopamine (DA) transporter (DAT) facilitates high-affinity presynaptic DA reuptake that temporally and spatially constrains DA neurotransmission. Aberrant DAT function is implicated in attention-deficit/hyperactivity disorder and autism spectrum disorder. DAT is a major psychostimulant target, and psychostimulant reward strictly requires binding to DAT. DAT function is acutely modulated by dynamic membrane trafficking at the presynaptic terminal and a PKC-sensitive negative endocytic mechanism, or “endocytic brake,” controls DAT plasma membrane stability. However, the molecular basis for the DAT endocytic brake is unknown, and it is unknown whether this braking mechanism is unique to DAT or common to monoamine transporters. Here, we report that the cdc42-activated, nonreceptor tyrosine kinase, Ack1, is a DAT endocytic brake that stabilizes DAT at the plasma membrane and is released in response to PKC activation. Pharmacologic and shRNA-mediated Ack1 silencing enhanced basal DAT internalization and blocked PKC-stimulated DAT internalization, but had no effects on SERT endocytosis. Both cdc42 activation and PKC stimulation converge on Ack1 to control Ack1 activity and DAT endocytic capacity, and Ack1 inactivation is required for stimulated DAT internalization downstream of PKC activation. Moreover, constitutive Ack1 activation is sufficient to rescue the gain-of-function endocytic phenotype exhibited by the ADHD DAT coding variant, R615C. These findings reveal a unique endocytic control switch that is highly specific for DAT. Moreover, the ability to rescue the DAT(R615C) coding variant suggests that manipulating DAT trafficking mechanisms may be a potential therapeutic approach to correct DAT coding variants that exhibit trafficking dysregulation.</p>
</abstract>
<kwd-group>
<kwd>dopamine</kwd>
<kwd>ADHD</kwd>
<kwd>membrane trafficking</kwd>
<kwd>tyrosine kinase</kwd>
<kwd>reuptake</kwd>
</kwd-group>
<funding-group>
<award-group id="gs1">
<funding-source id="sp1">HHS | NIH | National Institute on Drug Abuse (NIDA)<named-content content-type="funder-id">100000026</named-content></funding-source>
<award-id rid="sp1">DA035224</award-id>
</award-group>
</funding-group>
<counts>
<page-count count="6"></page-count>
</counts>
</article-meta>
</front>
</article>
</pmc-articleset>